United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases 5,400 Shares of Zoetis Inc. (NYSE:ZTS)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its position in Zoetis Inc. (NYSE:ZTS) by 2.4% in the 4th quarter, HoldingsChannel reports. The firm owned 234,860 shares of the company’s stock after acquiring an additional 5,400 shares during the period. Zoetis makes up about 1.5% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s portfolio, making the stock its 22nd largest position. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $38,266,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZTS. Raymond James Financial Inc. bought a new stake in shares of Zoetis during the 4th quarter worth about $196,651,000. Polen Capital Management LLC lifted its position in Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock worth $1,219,237,000 after acquiring an additional 1,116,541 shares during the last quarter. Amundi boosted its holdings in shares of Zoetis by 46.2% during the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock worth $453,355,000 after acquiring an additional 867,993 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Zoetis by 296.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after purchasing an additional 665,331 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $215.90.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 over the last quarter. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Down 1.2 %

Shares of NYSE:ZTS opened at $161.29 on Wednesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company has a market capitalization of $72.22 billion, a PE ratio of 29.49, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a fifty day moving average of $166.64 and a 200-day moving average of $175.02.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.